Infinity's horizons broaden with rich AbbVie co-development deal
This article was originally published in Scrip
Infinity Pharmaceuticals will expand its capacity for single-agent and combination therapy oncology studies for duvelisib (IPI-145), and improve its ability to pay future milestone and royalty fees under prior agreements, through an $805m partnership with AbbVie.
You may also be interested in...
Infinity's hopes for accelerated approval of duvelisib based on the DYNAMO study have been dashed, so as the company plots a new strategy for the PI3K inhibitor – with or without its partner AbbVie – it has cut discovery research operations, including 46 jobs.
ARCH Venture Partners brought in $2.975bn for its latest fund to give additional long-term investors a place at the table as the VC firm creates, builds and supports new early-stage biotechnology start-ups.
The company’s lipid nanoparticle technology can deliver mRNA, gene editing and other cargoes to multiple cell and organ types. ReCode aims to expand its pipeline beyond lung diseases.